286 related articles for article (PubMed ID: 32742264)
21. Molecular pathogenesis of myelodysplastic syndromes.
Visconte V; Selleri C; Maciejewski JP; Tiu RV
Transl Med UniSa; 2014 Jan; 8():19-30. PubMed ID: 24778995
[TBL] [Abstract][Full Text] [Related]
22. An update on the treatment of myelodysplastic syndromes.
Kurtin SE; Demakos EP
Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
[TBL] [Abstract][Full Text] [Related]
23. Therapy-related myelodysplastic syndrome.
Candelaria M; Dueñas-Gonzalez A
Expert Opin Drug Saf; 2015 May; 14(5):655-65. PubMed ID: 25675961
[TBL] [Abstract][Full Text] [Related]
24. Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine.
Moudra A; Hubackova S; Machalova V; Vancurova M; Bartek J; Reinis M; Hodny Z; Jonasova A
Oncoimmunology; 2016; 5(10):e1183860. PubMed ID: 27853634
[TBL] [Abstract][Full Text] [Related]
25. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
27. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
28. The mesenchymal compartment in myelodysplastic syndrome: Its role in the pathogenesis of the disorder and its therapeutic targeting.
Pontikoglou CG; Matheakakis A; Papadaki HA
Front Oncol; 2023; 13():1102495. PubMed ID: 36761941
[TBL] [Abstract][Full Text] [Related]
29. Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes.
Drexler HG
Leuk Res; 2000 Feb; 24(2):109-15. PubMed ID: 10654445
[TBL] [Abstract][Full Text] [Related]
30. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.
Abou Zahr A; Saad Aldin E; Komrokji RS; Zeidan AM
J Blood Med; 2015; 6():1-16. PubMed ID: 25565910
[TBL] [Abstract][Full Text] [Related]
31. [Research progress in MDS mouse model- review].
Zhang Y; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1272-9. PubMed ID: 23114163
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
33. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes.
Cull AH; Rauh MJ
J Leukoc Biol; 2017 Aug; 102(2):209-219. PubMed ID: 28596252
[TBL] [Abstract][Full Text] [Related]
34. In vitro study of biological characteristics of mesenchymal stem cells in patients with low-risk myelodysplastic syndrome.
Zhang YZ; Zhao DD; Han XP; Jin HJ; Da WM; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):813-8. PubMed ID: 18718067
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow niches in myelodysplastic syndromes.
Tosato G; Feng JX; Ohnuki H; Sim M
J Cancer Metastasis Treat; 2021; 7():. PubMed ID: 34746416
[TBL] [Abstract][Full Text] [Related]
36. Why Single-Cell Sequencing Has Promise in MDS.
Zhang X; Grimes HL
Front Oncol; 2021; 11():769753. PubMed ID: 34926276
[TBL] [Abstract][Full Text] [Related]
37. Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide.
Beier F; Masouleh BK; Buesche G; Ventura Ferreira MS; Schneider RK; Ziegler P; Wilop S; Vankann L; Gattermann N; Platzbecker U; Giagounidis A; Götze KS; Nolte F; Hofmann WK; Haase D; Kreipe H; Panse J; Blasco MA; Germing U; Brümmendorf TH
Leuk Res; 2015 Sep; ():. PubMed ID: 26427727
[TBL] [Abstract][Full Text] [Related]
38. Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS.
Velegraki M; Stiff A; Papadaki HA; Li Z
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013147
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes.
Aul C; Bowen DT; Yoshida Y
Haematologica; 1998 Jan; 83(1):71-86. PubMed ID: 9542325
[TBL] [Abstract][Full Text] [Related]
40. Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells.
Mian SA; Abarrategi A; Kong KL; Rouault-Pierre K; Wood H; Oedekoven CA; Smith AE; Batsivari A; Ariza-McNaughton L; Johnson P; Snoeks T; Mufti GJ; Bonnet D
Blood Cancer Discov; 2021 Mar; 2(2):135-145. PubMed ID: 33778768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
